Chardan Capital Reiterates “Buy” Rating for Cognition Therapeutics (NASDAQ:CGTX)

Cognition Therapeutics (NASDAQ:CGTX)‘s stock had its “buy” rating reiterated by analysts at Chardan Capital in a report released on Friday,Benzinga reports. They presently have a $11.00 price objective on the stock.

A number of other analysts have also recently commented on the company. B. Riley reaffirmed a “neutral” rating and set a $1.00 price target (down previously from $5.00) on shares of Cognition Therapeutics in a research report on Tuesday, August 6th. Cantor Fitzgerald downgraded Cognition Therapeutics from an “overweight” rating to a “neutral” rating in a report on Tuesday, July 30th. Finally, HC Wainwright reiterated a “buy” rating and issued a $5.00 target price on shares of Cognition Therapeutics in a research report on Monday, November 4th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, Cognition Therapeutics has an average rating of “Moderate Buy” and an average target price of $8.00.

Cognition Therapeutics Price Performance

Cognition Therapeutics stock traded down $0.05 during mid-day trading on Friday, reaching $0.46. 332,087 shares of the company traded hands, compared to its average volume of 493,689. The firm’s fifty day moving average is $0.50 and its two-hundred day moving average is $1.22. The company has a market capitalization of $18.51 million, a price-to-earnings ratio of -0.48 and a beta of 1.34. Cognition Therapeutics has a fifty-two week low of $0.34 and a fifty-two week high of $2.95.

Institutional Investors Weigh In On Cognition Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Sigma Planning Corp grew its position in shares of Cognition Therapeutics by 14.6% during the 3rd quarter. Sigma Planning Corp now owns 197,190 shares of the company’s stock valued at $92,000 after acquiring an additional 25,050 shares during the period. Mercer Global Advisors Inc. ADV increased its position in shares of Cognition Therapeutics by 33.4% in the second quarter. Mercer Global Advisors Inc. ADV now owns 95,951 shares of the company’s stock valued at $159,000 after buying an additional 24,050 shares in the last quarter. CM Management LLC raised its stake in shares of Cognition Therapeutics by 14.3% during the 2nd quarter. CM Management LLC now owns 200,000 shares of the company’s stock worth $332,000 after buying an additional 25,000 shares during the period. Bangor Savings Bank lifted its position in shares of Cognition Therapeutics by 41.6% during the 2nd quarter. Bangor Savings Bank now owns 34,019 shares of the company’s stock valued at $56,000 after buying an additional 10,000 shares in the last quarter. Finally, Levin Capital Strategies L.P. acquired a new stake in Cognition Therapeutics in the 1st quarter valued at $55,000. Institutional investors and hedge funds own 43.35% of the company’s stock.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.